| |
| Peptide-affinity Purified Polyclonal Antibody to p38 MAPK (Tyr182) |
| Catalog No | : | IMG-90316-1 | | Contents | : | Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. | | Isotype | : | Rabbit IgG | | Purification | : | Prepared from rabbit serum by affinity purification via sequential chromatography on phospho and dephosphopeptide affinity columns. | | Species React | : | Human, Mouse, Rat | | Host | : | Rabbit | | | Application
Western Blot: 1:500-1:1000
IHC (paraffin): 1:50-1:100
Storage
Store at -20°C.
Recommended Positive Control : NIH-3T3, cos7 and K562 cells |
|
Background
The three Mitogen-Activated Protein Kinases (MAPKs) are evolutionarily conserved protein kinases that control a vast array of cellular processes. P38 MAPK is one these kinases and it is activated by both inflammatory cytokines and by stress. The P38 MAPK is thought to be particularly important in diseases like asthma and autoimmunity but it also plays important roles in the stress response of the nervous system. Like the other MAPKs, p38 is activated by a dual specificity kinase that phosphorylates Thr180 and Tyr182. |
Antigen
This antibody was generated by immunizing rabbits with a synthetic phosphopeptide corresponding to human MAPK around the phosphorylation site of tyrosine 182 (T-G-YP-V-A).
|
Genebank Info (Protein)
NP_004933
|
|
 | Western blot analysis of p38 MAPK (Tyr182) in IMG-90316-1 in NIH-3T3 (Line 1 and 4) and cos7 (Line 2 and 5) and K562 (Line 3 and 6) cells, untreated or treated with UV (20min). | | | |  | Immunohistochemical analysis of p38 MAPK (Tyr182) in paraffin-embedded human breast carcinoma tissue, using IMG-90316-1. | | | |
|
|
|
Reference
1. Lin, A. et al. Science. 268:286-290 (1995)..
2. Choe, ES. et al. Neurosci. 101:607-617 (2000)..
|
|
Product Citations
1. Carmide-dependent PP2A regulation of TNF-α induced IL-8 production in respiratory epithelial cells. AJP doi:10.1152/ajplung.90516.2008 (2009). WB (human alveolar epithelial cell line A549), Fig. 3A.
|
|
|
|
